Placebo to MK-7339 150 mg clinical trials

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

This study is looking at new ways to treat a type of lung cancer that has spread. It combines standard chemotherapy with a newer drug, pembrolizumab, and sometimes involves another drug, olaparib, to see if this mix works better.